VX-103 is under clinical development by Vaxess Technologies and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections. According to GlobalData, Phase I drugs for Influenza A Virus, H1N1 Subtype Infections have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VX-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VX-103 overview

VX-103 is under development for the prevention of seasonal influenza and influenza A H1N1 infections. It is a H1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch (MAP) system). It is administered through intradermal route as patch. It is a pentavalent vaccine and is being developed based on MIMIX sustained-release microneedle patch platform and silk protein based vaccine technology.

Vaxess Technologies overview

Vaxess Technologies (Vaxess) is a biotechnology company that focuses on the development of next-generation drug delivery products. Its proprietary MIMIX technology is used in developing therapies for oncology and infectious disease. Vaxess MIMIX technology redefines non-invasive, biodegradable and controlled delivery of medicines not requiring refrigeration. The company’s MIMIX platform enables sustained dermal delivery of a wide range of therapeutics and vaccines. Vaxess is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of VX-103’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.